This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Castles, C. G. Articles by Hill, S. M. Search for Related Content PubMed PubMed Citation Articles by Castles, C. G. Articles by Hill, S. M.

Expression of a Constitutively Active Estrogen Receptor Variant in the Estrogen Receptor-negative BT-20 Human Breast Cancer Cell Line¹

Department of Anatomy and Molecular and Cellular Biology Program, Tulane University School of Medicine, New Orleans, Louisiana 70112 [C. G. C., D. M. K., S. M. H.], and Department of Medicine/Oncology, University of Texas Health Science Center, San Antonio, Texas 78284 [S. A. W. F.]

Estrogen receptor (ER) expression by breast tumors is an important predictor of disease-free survival in breast cancer patients and, more importantly, is a strong predictor of response to endocrine therapy. Variant forms of the ER may play an important role in the loss of hormone responsiveness and the progression to hormone independence. We have examined a panel of human breast tumor cell lines, both ER-positive and ER-negative, and have identified an ER mRNA variant containing a deletion of exon 5 in the ER-negative BT-20 and ER-positive MCF-7 cell lines. This exon 5 deletion variant has been previously reported to be overexpressed in ER-negative/progesterone receptor-positive breast tumors. Using RNase protection analysis, we have found that the predominant ER transcript in the BT-20 cells is the exon 5 deletion variant, while the principal transcript in MCF-7 cells is the wild-type ER mRNA. The variant ER transcript is translated into a truncated receptor protein of approximately M_r 42,000 when expressed in yeast and, more important, in breast tumor cells. This is the first demonstration of an exon 5 deletion variant ER protein. Functional analysis has shown that this variant ER possesses constitutive transcriptional regulatory activity with respect to an estrogen-regulated reporter gene construct in a yeast expression system. The presence of this ER variant in breast tumor cell lines, as well as breast tumor biopsies and uterine tissue, suggests that it is a naturally occurring variant that may arise by alternative splicing, and whose overexpression may be involved in the progression of breast tumors to a hormone-independent state.

¹ Supported by American Cancer Society Grant IN-1331 to S. M. H. and NIH Grants CA52351 and CA30195 to S. A. W. F.

² To whom requests for reprints should be addressed, at Department of Anatomy, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112.

Received 7/ 2/93. Accepted 10/ 5/93.

This article has been cited by other articles:

				O. Dalmizrak, A. Wu, J. Chen, H. Sun, F. E. Utama, D. Zambelli, T. H. Tran, H. Rui, and R. Baserga Insulin Receptor Substrate-1 Regulates the Transformed Phenotype of BT-20 Human Mammary Cancer Cells Cancer Res., March 1, 2007; 67(5): 2124 - 2130. [Abstract] [Full Text] [PDF]

				N Sarwar, J-S Kim, J Jiang, D Peston, H D Sinnett, P Madden, J M Gee, R I Nicholson, A E Lykkesfeldt, S Shousha, et al. Phosphorylation of ER{alpha} at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ER{alpha} phosphorylation in breast cancer progression. Endocr. Relat. Cancer, September 1, 2006; 13(3): 851 - 861. [Abstract] [Full Text] [PDF]

				J. Chen, A. Wu, H. Sun, R. Drakas, C. Garofalo, S. Cascio, E. Surmacz, and R. Baserga Functional Significance of Type 1 Insulin-like Growth Factor-mediated Nuclear Translocation of the Insulin Receptor Substrate-1 and {beta}-Catenin J. Biol. Chem., August 19, 2005; 280(33): 29912 - 29920. [Abstract] [Full Text] [PDF]

				W. Bryant, A. E. Snowhite, L. W. Rice, and M. A. Shupnik The Estrogen Receptor (ER){alpha} Variant {Delta}5 Exhibits Dominant Positive Activity on ER-Regulated Promoters in Endometrial Carcinoma Cells Endocrinology, February 1, 2005; 146(2): 751 - 759. [Abstract] [Full Text] [PDF]

				M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF]

				A. Sapino, P. Cassoni, E. Ferrero, M. Bongiovanni, L. Righi, N. Fortunati, P. Crafa, R. Chiarle, and G. Bussolati Estrogen Receptor {alpha} Is a Novel Marker Expressed by Follicular Dendritic Cells in Lymph Nodes and Tumor-Associated Lymphoid Infiltrates Am. J. Pathol., October 1, 2003; 163(4): 1313 - 1320. [Abstract] [Full Text] [PDF]

				J. M. Garcia Pedrero, P. Zuazua, C. Martinez-Campa, P. S. Lazo, and S. Ramos The Naturally Occurring Variant of Estrogen Receptor (ER) ER{Delta}E7 Suppresses Estrogen-Dependent Transcriptional Activation by Both Wild-Type ER{alpha} and ER{beta} Endocrinology, July 1, 2003; 144(7): 2967 - 2976. [Abstract] [Full Text] [PDF]

				A. Bollig and R. J. Miksicek An Estrogen Receptor-{alpha} Splicing Variant Mediates Both Positive and Negative Effects on Gene Transcription Mol. Endocrinol., May 1, 2000; 14(5): 634 - 649. [Abstract] [Full Text]

				C. Donaghue, B. R. Westley, and F. E. B. May Selective Promoter Usage of the Human Estrogen Receptor-{alpha} Gene and Its Regulation by Estrogen Mol. Endocrinol., November 1, 1999; 13(11): 1934 - 1950. [Abstract] [Full Text]

				R. L. Balleine, S. M. N. Hunt, and C. L. Clarke Coexpression of Alternatively Spliced Estrogen and Progesterone Receptor Transcripts in Human Breast Cancer J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1370 - 1377. [Abstract] [Full Text]

				M. A. Shupnik, L. K. Pitt, A. Y. Soh, A. Anderson, M. B. Lopes, and E. R. Laws Jr. Selective Expression of Estrogen Receptor {alpha} and {beta} Isoforms in Human Pituitary Tumors J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3965 - 3972. [Abstract] [Full Text]

				S. S. Chaidarun and J. M. Alexander A Tumor-Specific Truncated Estrogen Receptor Splice Variant Enhances Estrogen-Stimulated Gene Expression Mol. Endocrinol., September 1, 1998; 12(9): 1355 - 1366. [Abstract] [Full Text]

				I. Erenburg, B. Schachter, R. M. y Lopez, and L. Ossowski Loss of an Estrogen Receptor Isoform (ER{alpha}{Delta}3) in Breast Cancer and the Consequences of Its Reexpression: Interference with Estrogen-Stimulated Properties of Malignant Transformation Mol. Endocrinol., December 1, 1997; 11(13): 2004 - 2015. [Abstract] [Full Text] [PDF]

				I. Treilleux, N. Peloux, M. Brown, and A. Sergeant Human Estrogen Receptor (ER) Gene Promoter-P1: Estradiol-Independent Activity and Estradiol Inducibility in ER+ and ER- Cells Mol. Endocrinol., August 1, 1997; 11(9): 1319 - 1331. [Abstract] [Full Text]